This vaccine is designed to prevent infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58, which is expected to provide broader protection than the current vaccine in the market and have much lower production costs. Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and has a 60% interest in the project.
Dr Liang Qiao, chairman and CEO of Bio-Bridge said, “We believe that our agreement with the Chinese Academy of Medical Sciences will enable us to solidify our research capability in China as we try to introduce more potential vaccine products in addition to our current vaccine pipeline.”
The Chinese Academy of Medical Sciences was established in 1956 and is the national level medical science research center in China.